Toyama, Japan

Sakiko Takeshima

This inventor holds 2 USPTO granted patents and 4 published patent applications and 2 EPO patents. Top assignee: Toyama Chemical Co., Ltd.. Active years: 2015.

USPTO Granted Patents = 2 

% Patents Active = 100.0

 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2015

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Sakiko Takeshima: Innovator in Pharmaceutical Chemistry

Introduction

Sakiko Takeshima is a notable inventor based in Toyama, Japan. She has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds with enhanced solubility for medical applications. With a total of 2 patents, her work is recognized for its potential impact on drug formulation and delivery.

Latest Patents

Takeshima's latest patents include the following innovations:

1. **Sodium salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide** - This preparation is characterized by its superior solubility, making it useful as a preparation for injection.

2. **Meglumine salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide** - Similar to her previous work, this preparation also boasts superior solubility and is designed for injection purposes.

Career Highlights

Sakiko Takeshima is currently employed at Toyama Chemical Co., Ltd., where she continues to innovate in the pharmaceutical sector. Her research focuses on improving the solubility of compounds, which is crucial for effective drug delivery.

Collaborations

Some of her notable coworkers include Keiko Takakura and Namika Nakamatsu, who contribute to the collaborative environment that fosters innovation at Toyama Chemical Co., Ltd.

Conclusion

Sakiko Takeshima's contributions to pharmaceutical chemistry through her patents demonstrate her commitment to advancing medical science. Her work not only enhances drug formulations but also paves the way for future innovations in the field.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…